

# Medicare Monthly Review

Issue No. MMR 2020-05

May 2020

## In This Issue

### National Government Services – Articles for Part A and Part B Providers

- [LCD and Article Revisions: May 2020](#).....2

### CMS MLN Connects<sup>®</sup> Weekly Provider eNews

- [MLN Connects<sup>®</sup> Special Edition for April 30, 2020](#)
- [MLN Connects<sup>®</sup> for April 30, 2020](#)
- [MLN Connects<sup>®</sup> Special Edition for Monday, April 27, 2020](#)
- [MLN Connects<sup>®</sup> for April 23, 2020](#)
- [MLN Connects<sup>®</sup> Special Edition for Monday, April 20, 2020](#)
- [MLN Connects<sup>®</sup> Special Edition for Friday, April 17, 2020](#)
- [MLN Connects<sup>®</sup> for April 16, 2020](#)
- [MLN Connects<sup>®</sup> Special Edition for Wednesday, April 15, 2020](#)
- [MLN Connects<sup>®</sup> Special Edition for Friday, April 10, 2020](#)
- [MLN Connects<sup>®</sup> for April 9, 2020](#)
- [MLN Connects<sup>®</sup> Special Edition for Tuesday, April 7, 2020](#)
- [MLN Connects<sup>®</sup> Special Edition for Friday, April 3, 2020](#)
- [MLN Connects<sup>®</sup> for April 2, 2020](#)

Contact information can be found on our website.  
Medicare policies can be accessed from the Medical Policy Center section of our website. Providers without access to the Internet can request hard copies from National Government Services.

CPT five-digit codes, descriptions and other data only are copyright 2018 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for data contained or not contained herein.  
Applicable FARS/DFARS clauses apply.

This bulletin should be shared with all health care practitioners and managerial members of the providers/suppliers staff. Bulletins issued during the last two years are available at no cost from our website.

CMS publishes the Quarterly Provider Update (QPU) at the beginning of each quarter to inform providers and suppliers:

- Regulations and major policies under development during the quarter
- Regulations and major policies completed or cancelled
- New or revised manual instructions

## **National Government Services – LCD and Articles for Part A and Part B Providers**

### **LCD and Article Revisions: May 2020**

#### **Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH) (L38367)**

The Notice period has been extended to August 31, 2020. The Notice period start date has been changed to April 30, 2020. The Revision Effective Date has been changed from April 1, 2020 to September 1, 2020.

#### **Billing and Coding: Bevacizumab and biosimilars (A52370)**

Based on compendia review, ICD-10-CM codes G96.8, T66.XXXA, T66.XXXD and T66.XXXS have been added effective for dates of service on or after 05/01/2020. The following has been added to the ICD-10 Codes Asterisk Explanation section: ICD-10-CM code G96.8 must be billed with ICD-10-CM code T66.XXXA, T66.XXXD or T66.XXXS.

#### **Billing and Coding: Bortezomib (A52371)**

Based on compendia review, ICD-10-CM codes C46.0, C46.1, C46.2, C46.3, C46.4, C46.51, C46.52, C46.7, C91.00 and C91.02 have been added effective for dates of service on or after 05/01/2020.

#### **Billing and Coding: Filgrastim, Pegfilgrastim, Tbo-filgrastim and biosimilars (A52408)**

Based on Transmittal 4543, HCPCS code C9058 has been added to the “CPT/HCPCS Codes Group 1 Paragraph” section and the CPT/HCPCS section of the article to report pegfilgrastim-bmez for Part A services.

#### **Billing and Coding: Infliximab and biosimilars (A52423)**

Based on compendia review, ICD-10-CM codes I44.0, I44.1, I44.2, I44.39, I45.0, I45.19, I45.2, I45.3, I45.4, I45.5, I45.6, I45.81 and I45.89 have been added to Group 3 effective for dates of service on or after 05/01/2020.

#### **Billing and Coding: Intravenous Immune Globulin (IVIG) (A52446)**

Based on compendia review, ICD-10-CM codes I44.0, I44.1, I44.2, I44.39, I45.0, I45.19, I45.2, I45.3, I45.4, I45.5, I45.6, I45.81 and I45.89 have been added effective for dates of service on or after 05/01/2020.

#### **Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (A52453)**

Based on compendia review, ICD-10-CM codes D25.0, D25.1, D25.2, N60.11, N60.12, N80.0 and N85.01 have been added for HCPCS code J3315 (Group 2), ICD-10-CM code E30.1 has been added for HCPCS code J9202 (Group 4) and ICD-10-CM codes D25.0, D25.1 and D25.2 have been added for HCPCS code J9217 (Group 6) effective for dates of service on or after 05/01/2020.

#### **Billing and Coding: Molecular Pathology Procedures (A56199)**

The following wording for CPT code 81445 was corrected:

"please refer to LCD L36376" was revised to read "please refer to LCD L37810".

#### **Billing and Coding: Nivolumab (A54862)**

Based on compendia review, ICD-10-CM codes C21.2, C84.Z1-C84.Z9 and C86.0 have been added effective for dates of service on or after 05/01/2020. The last sentence in the “Utilization Guidelines” has been changed to: If the PD-1 directed agent was discontinued for reasons other than disease progression, then nivolumab may be used when an approved indication is met.